InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
-0.9%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by ADAMS ADRIAN, Director. Insider active across 5 companies, notably Akebia Therapeutics, Inc.. Aggregated, 15 filings have been recorded. Split: 2 buys · 0 sell. Total volume traded: €406k. Activity tracked since 2 June 2021. The latest transaction was filed on 24 June 2024 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations15 total
5,100 sharesCommon StockSEC:0001248144-26-000003:0
35,700 sharesCommon StockSEC:0001248144-26-000001:0
2,174 shares0Common StockSEC:0001415889-24-018074:0
30,000 shares0Common StockSEC:0001562180-24-004901:0
581 shares0Common StockSEC:0001209191-23-058474:0
30,000 shares0Common StockSEC:0001562180-23-004956:0
15,500 shares0Common StockSEC:0001209191-22-042308:0
13,700 shares0Common StockSEC:0001562180-22-004973:0
17,203 shares@ US$13.806150.0% of flowCommon StockSEC:0001209191-21-052595:0
Ideal exit: 15 May 2022 (T+270)
17,203 shares@ US$13.806150.0% of flowCommon StockSEC:0001209191-21-052595
Ideal exit: 15 May 2022 (T+270)
10,000 shares0Common StockSEC:0001209191-21-041579
10,000 shares0Common StockSEC:0001209191-21-041579:0
13,700 shares0Common StockSEC:0001562180-21-004026:0
13,700 shares0Common StockSEC:0001562180-21-004026
2,944,888 sharesCommon SharesSEC:0001104659-16-095179:0
15 of 15 declarations
About ADAMS ADRIAN
Adrian Adams serves as Director, Chairman, CEO, and President at Akebia Therapeutics, Inc., ACELRX Pharmaceuticals Inc., and Impel Neuropharma Inc. He is responsible for the strategic and operational leadership of these companies, ensuring their growth and development. Adams brings extensive experience in the biopharmaceutical sector, contributing to innovation and improving patient outcomes.
